Abstract
This phase 1 study examined the safety, maximum-tolerated dose (MTD) and antitumour activity of E7449, a novel PARP 1/2 and tankyrase 1/2 inhibitor. E7449 was orally administered once daily in 28-day cycles to patients with advanced solid tumours (50-800-mg doses). Archival tumour samples from consenting patients were evaluated for the expression of 414 genes in a biomarker panel (2X-121 drug-response predictor [DRP]) found to be predictive of the response to E7449 in cell lines. Forty-one patients were enrolled (13 pancreatic, 5 ovarian, 4 each with breast, lung or colorectal cancer and 11 with other tumour types). The most common grade ≥3 treatment-related adverse event was fatigue (n = 7, 17.1%). Five patients experienced a dose-limiting toxicity (fatigue, n = 4, 800 mg; anaphylaxis, n = 1, 600 mg) for an MTD of 600 mg. E7449 exhibited antitumour activity in solid tumours, including 2 partial responses (PRs), and stable disease (SD) in 13 patients, which was durable (>23 weeks) for 8 patients. In 13 patients, the 2X-121 DRP identified those achieving PR and durable SD. E7449 showed good tolerability, promising antitumour activity and significant concentration-dependent PARP inhibition following 50-800-mg oral dosing. The res...Continue Reading
References
Oct 1, 1994·Clinical Pharmacology and Therapeutics·W J Jusko, H C Ko
Aug 24, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lucio TentoriGrazia Graziani
Sep 20, 2008·Journal of Medicinal Chemistry·Keith A MenearNiall M B Martin
Feb 12, 2009·British Medical Bulletin·Anthony J Chalmers
Oct 31, 2009·Journal of Medicinal Chemistry·Philip JonesMichael Rowley
Feb 23, 2010·Molecular Immunology·Marisa Galbis-MartínezJosé Yélamos
Mar 5, 2010·Nature Reviews. Cancer·Michèle RouleauGuy G Poirier
Mar 9, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Francesca NastaClaudio Pioli
Oct 5, 2010·Scandinavian Journal of Immunology·R CabreraD R Nelson
Jan 6, 2012·PloS One·Thomas KarnAchim Rody
Jul 14, 2012·Current Medicinal Chemistry·D DavarH Tawbi
Nov 24, 2012·Nature Reviews. Cancer·Nicola J Curtin
Jan 29, 2013·Immunity·Wei LiaoWarren J Leonard
Aug 27, 2013·PloS One·Pin ZhangWanjun Chen
Dec 21, 2013·Molecular Cancer Therapeutics·Junko MuraiYves Pommier
May 23, 2014·Cytokine·Sheikh Fayaz AhmadSabry M Attia
Nov 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bella KaufmanSusan M Domchek
Mar 12, 2015·The Journal of Pharmacology and Experimental Therapeutics·Yuqiao ShenBing Wang
Mar 31, 2015·Gynecologic Oncology·Robert L ColemanElizabeth M Swisher
Oct 3, 2015·The Journal of Biological Chemistry·Xuerui LuoBin Li
Oct 30, 2015·Oncotarget·Sharon McGonigleKenichi Nomoto
Dec 26, 2015·Nucleic Acids Research·Amanda A RiccioJohn M Pascal
Apr 30, 2016·Clinical Pharmacology in Drug Development·Diane D WangRuth Plummer
Oct 9, 2016·The New England Journal of Medicine·Mansoor R MirzaUNKNOWN ENGOT-OV16/NOVA Investigators
Oct 14, 2016·British Journal of Cancer·G E Konecny, R S Kristeleit
Jan 13, 2017·Drugs·Geraldine O'Sullivan CoyneJames H Doroshow
Jan 15, 2017·Seminars in Cell & Developmental Biology·Caleb DulaneyEddy S Yang
Mar 8, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca KristeleitRonnie Shapira-Frommer
May 12, 2017·Therapeutic Advances in Medical Oncology·Tarra Evans, Ursula Matulonis
Mar 23, 2018·PloS One·Ida Kappel BuhlJens Benn Sørensen
Aug 14, 2018·Breast Cancer Research and Treatment·Anna Sofie Kappel BuhlPeter Buhl Jensen
Sep 22, 2018·Cancer Science·Anna MizutaniHiroyuki Seimiya
Oct 23, 2018·The New England Journal of Medicine·Kathleen MoorePaul DiSilvestro
Nov 30, 2018·International Journal of Molecular Sciences·Mathieu CésaireFrançois Chevalier
Citations
Dec 22, 2020·Advanced Drug Delivery Reviews·Michal CaspiRina Rosin-Arbesfeld
Feb 12, 2021·Expert Opinion on Therapeutic Patents·Chirag C Mehta, Hardik G Bhatt
Jan 21, 2021·MBio·Nathan E StoneChristopher T French
May 1, 2021·Cancers·Máté A Demény, László Virág
Jul 3, 2021·Cancers·Sandy ChevrierRomain Boidot
Aug 10, 2021·ACS Omega·Ahmed E FazaryAly F Mohamed
Sep 15, 2021·Cancer Discovery·Marie J ParsonsLukas E Dow
Sep 17, 2021·Blood Advances·Christina-Nefeli KontandreopoulouNora-Athina Viniou
Feb 8, 2022·Future Oncology·Zuzanna ChilimoniukAgata Filip